OncoSec Medical to Present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum
SAN DIEGO-- OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present a corporate overview of the company at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum at the New York Academy of Sciences on Wednesday, March 19th at 3:00 p.m. (EST).
A webcast will be available one week after the presentation on OncoSec’s web page at http://www.oncosec.com.
About the Sachs Cancer Bio Partnering & Investment Forum
The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum aims to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma, and biotech to facilitate partnering and investments. Over 200 delegates are expected to attend, with meeting facilities and an online meeting system to make the event transactional. The Sachs Cancer Bio Partnering & Investment Forum will take place March 19th, 2014, at the New York Academy of Sciences, at 250 Greenwich Street, New York, NY.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical’s core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated positive safety and preliminary efficacy in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the toxicities associated with other systemic treatments. OncoSec’s clinical programs currently include three Phase 2 trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma (http://clinicaltrials.gov/ct2/results?term=oncosec&Search=Search). As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications and efficacious combination approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
OncoSec Medical Inc.
Veronica Vallejo, CFO
Source: OncoSec Medical Inc.
Released March 17, 2014